Literature DB >> 21487661

Effects of lidocaine-induced inactivation of the bed nucleus of the stria terminalis, the central or the basolateral nucleus of the amygdala on the opponent-process actions of self-administered cocaine in rats.

Jennifer M Wenzel1, Stephanie A Waldroup, Zachary M Haber, Zu-In Su, Osnat Ben-Shahar, Aaron Ettenberg.   

Abstract

RATIONALE: In addition to its rewarding actions, cocaine has profound negative effects that are unmasked as the rewarding impact of the drug fades. While much is known about the neurobiology of cocaine reward, the mechanisms underlying the negative actions of the drug remain unclear.
OBJECTIVES: The current study investigates the role of three brain regions each implicated in the modulation of negative affective states-the bed nucleus of the stria terminalis (BNST), the central (CeA), and the basolateral (BLA) nucleus of the amygdala.
METHODS: The dual actions of cocaine were assessed using a runway self-administration procedure in which rats exhibit both approach to and avoidance of a goal box associated with cocaine administration (retreat behaviors). Here, rats ran a straight alley once/day for i.v. cocaine (1.0 mg/kg/injection) over 14 days during which the BNST, CeA, or BLA was inactivated via bilateral intracranial infusions of lidocaine (0 or 20 μg/0.5 μl/side) administered 15 min prior to testing. The impact of lidocaine on spontaneous locomotor activity was also assessed to rule out nonspecific actions of the treatments.
RESULTS: Control animals running for cocaine developed the expected pattern of approach-avoidance retreat behavior. Inactivation of the BNST attenuated such behavior, BLA inactivation had no appreciable effects, and CeA inactivation produced intermediate and more variable results. Locomotor activity was unaffected by any of the treatments.
CONCLUSIONS: These data suggest that the BNST and to a lesser extent the CeA, but not the BLA, play a role in mediating the opponent-process actions of self-administered cocaine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487661      PMCID: PMC3190140          DOI: 10.1007/s00213-011-2267-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  73 in total

1.  Neural systems involved in fear and anxiety measured with fear-potentiated startle.

Authors:  Michael Davis
Journal:  Am Psychol       Date:  2006-11

2.  Runway self-administration of intracerebroventricular cocaine: evidence of mixed positive and negative drug actions.

Authors:  Daniel Guzman; Aaron Ettenberg
Journal:  Behav Pharmacol       Date:  2007-02       Impact factor: 2.293

3.  The catecholaminergic innervation of the rat amygdala.

Authors:  E Asan
Journal:  Adv Anat Embryol Cell Biol       Date:  1998       Impact factor: 1.231

4.  Dissociable effects of lidocaine inactivation of the rostral and caudal basolateral amygdala on the maintenance and reinstatement of cocaine-seeking behavior in rats.

Authors:  Kathleen M Kantak; Yolanda Black; Eric Valencia; Kristen Green-Jordan; Howard B Eichenbaum
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

5.  Distribution and efferent projections of corticotropin-releasing factor-like immunoreactivity in the rat amygdaloid complex.

Authors:  M Sakanaka; T Shibasaki; K Lederis
Journal:  Brain Res       Date:  1986-09-24       Impact factor: 3.252

6.  Concurrent positive and negative goalbox events produce runway behaviors comparable to those of cocaine-reinforced rats.

Authors:  T D Geist; A Ettenberg
Journal:  Pharmacol Biochem Behav       Date:  1997 May-Jun       Impact factor: 3.533

7.  Inactivation of the bed nucleus of the stria terminalis in an animal model of relapse: effects on conditioned cue-induced reinstatement and its enhancement by yohimbine.

Authors:  Deanne M Buffalari; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2010-09-09       Impact factor: 4.530

8.  A role for the bed nucleus of the stria terminalis, but not the amygdala, in the effects of corticotropin-releasing factor on stress-induced reinstatement of cocaine seeking.

Authors:  S Erb; J Stewart
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

9.  Anxiolytic-like effects induced by acute reversible inactivation of the bed nucleus of stria terminalis.

Authors:  L B M Resstel; F H F Alves; D G Reis; C C Crestani; F M A Corrêa; F S Guimarães
Journal:  Neuroscience       Date:  2008-04-11       Impact factor: 3.590

10.  Anxiolytic effects of nicotine in a rodent test of approach-avoidance conflict.

Authors:  Ami Cohen; Robert W Young; Miguel A Velazquez; Mariya Groysman; Kavon Noorbehesht; Osnat M Ben-Shahar; Aaron Ettenberg
Journal:  Psychopharmacology (Berl)       Date:  2009-02-25       Impact factor: 4.530

View more
  18 in total

1.  Inactivation of the central nucleus of the amygdala reduces the effect of punishment on cocaine self-administration in rats.

Authors:  YueQiang Xue; Jeffery D Steketee; WenLin Sun
Journal:  Eur J Neurosci       Date:  2012-02-06       Impact factor: 3.386

2.  Weakening of negative relative to positive associations with cocaine-paired cues contributes to cue-induced responding after drug removal.

Authors:  Zu-In Su; Gleb Kichaev; Jennifer Wenzel; Osnat Ben-Shahar; Aaron Ettenberg
Journal:  Pharmacol Biochem Behav       Date:  2011-10-08       Impact factor: 3.533

3.  The dopamine antagonist cis-flupenthixol blocks the expression of the conditioned positive but not the negative effects of cocaine in rats.

Authors:  Jennifer M Wenzel; Zu-In Su; Kerisa Shelton; Hiram M Dominguez; Victoria A von Furstenberg; Aaron Ettenberg
Journal:  Pharmacol Biochem Behav       Date:  2013-09-05       Impact factor: 3.533

Review 4.  Functional Heterogeneity in the Bed Nucleus of the Stria Terminalis.

Authors:  Nur Zeynep Gungor; Denis Paré
Journal:  J Neurosci       Date:  2016-08-03       Impact factor: 6.167

5.  Attenuation of the anxiogenic effects of cocaine by 5-HT1B autoreceptor stimulation in the bed nucleus of the stria terminalis of rats.

Authors:  Adam K Klein; Michael A Brito; Sayeh Akhavan; Dylan R Flanagan; Nikki Le; Tatum Ohana; Anand S Patil; Erin M Purvis; Carl Provenzano; Alex Wei; Lucy Zhou; Aaron Ettenberg
Journal:  Psychopharmacology (Berl)       Date:  2016-11-25       Impact factor: 4.530

6.  Activation of 5-HT1B receptors in the Lateral Habenula attenuates the anxiogenic effects of cocaine.

Authors:  Adam K Klein; Erin M Purvis; Kathy Ayala; Lisette Collins; Jacob T Krug; Matthew S Mayes; Aaron Ettenberg
Journal:  Behav Brain Res       Date:  2018-04-13       Impact factor: 3.332

7.  Regulation of the ventral tegmental area by the bed nucleus of the stria terminalis is required for expression of cocaine preference.

Authors:  Gregory C Sartor; Gary Aston-Jones
Journal:  Eur J Neurosci       Date:  2012-10-08       Impact factor: 3.386

8.  Cocaine drives aversive conditioning via delayed activation of dopamine-responsive habenular and midbrain pathways.

Authors:  Thomas C Jhou; Cameron H Good; Courtney S Rowley; Sheng-Ping Xu; Huikun Wang; Nathan W Burnham; Alexander F Hoffman; Carl R Lupica; Satoshi Ikemoto
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

9.  Double Dissociation of Monoacylglycerol Lipase Inhibition and CB1 Antagonism in the Central Amygdala, Basolateral Amygdala, and the Interoceptive Insular Cortex on the Affective Properties of Acute Naloxone-Precipitated Morphine Withdrawal in Rats.

Authors:  Kiri L Wills; Gavin N Petrie; Geneva Millett; Cheryl L Limebeer; Erin M Rock; Micah J Niphakis; Benjamin F Cravatt; Linda A Parker
Journal:  Neuropsychopharmacology       Date:  2015-12-09       Impact factor: 7.853

10.  Noradrenergic β-receptor antagonism within the central nucleus of the amygdala or bed nucleus of the stria terminalis attenuates the negative/anxiogenic effects of cocaine.

Authors:  Jennifer M Wenzel; Samuel W Cotten; Hiram M Dominguez; Jennifer E Lane; Kerisa Shelton; Zu-In Su; Aaron Ettenberg
Journal:  J Neurosci       Date:  2014-03-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.